Patient-reported outcomes (PROs) from TITAN: A phase III, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) Meeting Abstract

Industry Collaboration International Collaboration

author list

  • Agarwal, N.; McQuarrie, K.; Bjartell, A.; Chowdhury, S.; Gomes, A. J. P. D. S.; Chung, B. H.; Ozguroglu, M.; Juarez Soto, A.; Merseburger, A.; Uemura, H.; Ye, D.; Given, R.; Miladinovic, B.; Dearden, L.; Deprince, K.; Naini, V.; Lopez-Gitlitz, A.; Chi, K. N.

publication date

  • October 1, 2019


published in



  • 30